EMA Oral Explanation Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Clinuvel accredits first European EPP expert centres
- Clinuvel Placement
- Clinuvel brief on European commercialisation
- US FDA orphan designation received for cutaneous porphyrias
- Update on North American vitiligo program for SCENESSE
Later from Clinuvel Pharmaceuticals
- Clinuvel declines unsolicited proposal from Retrophin
- EMA review of SCENESSE extended to mid-2014
- Media Release- Clinuvel successful in US Phase III trial
- Phase II vitiligo study commences in Singapore
- US orphan-drug designation in Hailey-Hailey Disease
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals